Is NCT06847269 recruiting in Memphis, TN?

Yes, NCT06847269 is currently recruiting participants at its Memphis, TN location. This acute lymphoblastic leukemia clinical trial is actively enrolling qualified participants.

How do I join the acute lymphoblastic leukemia clinical trial in Memphis?

To join this clinical trial in Memphis, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Memphis clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Acute Lymphoblastic Leukemia Clinical Trial in Memphis, TN

About This Acute Lymphoblastic Leukemia Study in Memphis

CAR19PK is a research study evaluating the use of lymphodepleting chemotherapy and chimeric antigen receptor (CAR) T cell therapy, a type of cellular therapy, for the treatment of refractory and/or relapsed leukemia. For this type of therapy, peripheral (circulating) immune cells are collected and then modified so that they can recognize an antigen, which is a particle present on the surface of a cancer cell. The CD19-CAR T cell product will be manufactured at the St. Jude Children's Research Hospital's Good Manufacturing Practice (GMP) facility. The main purpose of this study is to determine: * Evaluate different doses of fludarabine prior CAR T cell infusion * How your body processes fludarabine and cyclophosphamide, * How long the CAR T cells last in the body, * Whether or not treatment with this therapy is effective in treating people with refractory or relapsed leukemia, and * The side effects of this therapy.

Sponsor: St. Jude Children's Research Hospital

Who Can Participate

Inclusion Criteria

CD19+ leukemia\*\

with any of the following:

Refractory disease (primary or in relapse)

2nd or greater relapse

Any relapse after allogeneic hematopoietic cell transplantation

1st relapse if patient requires an allogeneic HCT as part of standard of care relapse therapy, but is found to be ineligible and/or unsuitable for HCT

must be confirmed to be CD19+ within 3 months prior to enrollment for treatment

Age: ≤ 21 years of age

Karnofsky or Lansky (age-dependent) performance score ≥ 50 (Appendix A)

Estimated life expectancy of \> 12 weeks. Patients with a history of prior allogeneic hematopoietic cell transplantation \[HCT\] must be clinically recovered from prior HCT therapy, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to apheresis

For females of child bearing age:

Not lactating with intent to breastfeed

Not pregnant with negative serum pregnancy test within 7 days prior to enrollment

Exclusion Criteria

Known primary immunodeficiency

History of HIV infection

Severe intercurrent bacterial, viral or fungal infection

History of hypersensitivity reactions to murine protein-containing products

Known contraindication to receiving protocol defined lymphodepleting chemotherapy regimen Treatment Inclusion Criteria:

Age: ≤ 21 years of age

Estimated life expectancy of \> 8 weeks

Detectable disease

Prior to planned CAR T cell infusion, patients with a history of prior allogeneic HCT must:

be at least 3 months from HCT

have no evidence of active GVHD

have not received a donor lymphocyte infusion (DLI) within the 28 days prior to planned infusion

Adequate cardiac function defined as left ventricular ejection fraction \> 40%, or shortening fraction ≥ 25%

EKG without evidence of clinically significant arrhythmia

Adequate renal function defined as creatinine clearance or radioisotope GFR ³ 50 ml/min/1.73m2 (GFR ³ 40 ml/min/1.73m2 if \< 2 years of age)

Adequate pulmonary function defined as forced vital capacity (FVC) ≥ 50% of predicted value; or pulse oximetry ≥ 92% on room air if patient is unable to perform pulmonary function testing

Karnofsky or Lansky (age-dependent) performance score ≥ 50 (Appendix A)

Total Bilirubin ≤ 3 times the upper limit of normal for age, except in subjects with Gilbert's syndrome

Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 times the upper limit of normal for age

Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy

For patients of child bearing age:

Not lactating with intent to breastfeed

Not pregnant with negative serum pregnancy test within 7 days prior to enrollment

If sexually active, agreement to use birth control until 6 months after T cell infusion. Exclusion Criteria:

Active CNS-3 disease

Known primary immunodeficiency

History of HIV infection

Evidence of active, uncontrolled neurologic disease

Severe, uncontrolled bacterial, viral or fungal infection

History of hypersensitivity reactions to murine protein-containing products

Known contraindication to receiving protocol defined lymphodepleting chemotherapy regimen

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Memphis?

Yes, this clinical trial (NCT06847269) has an active research site in Memphis, TN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Lymphoblastic Leukemia Treatment Options in Memphis, TN

If you're searching for acute lymphoblastic leukemia treatment options in Memphis, TN, this clinical trial (NCT06847269) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Memphis research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced acute lymphoblastic leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all acute lymphoblastic leukemia clinical trials near you to find additional studies recruiting in your area.

Acute Lymphoblastic Leukemia Clinical Trial in Memphis, TN

Expert Care in Memphis

IRB Approved

No-Cost Care

Apply for This Memphis Location

Why Participate?

Simple Process